Berberine-derived stack

B84· Mostly solid

Public • 10 Feb 2026

Targets glucose & lipid markers for long-term metabolic health.

← Back Try alternative layout

Buy stack

Berberine-derived stack

metabolic longevity healthspan

Berberine

Daily

MODERATE

10000mg

Coenzyme Q10

Daily

MODERATE

200mg

No interactions detected

Each dose includes evidence rationale · doses personalized to your weight

Stack note

Private note on this stack

Track how this stack felt, what you want to change next cycle, or anything you want to save privately in your member zone.

AI risk assessment

Context: No wearable data

PROAI risk assessment is available with Pro.

See plans

Stack pre-check

No personal data connected — connect wearables or upload bloodwork for a personalised check

Clean

Supplements

Training load

Unknown

No flags

No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis

Pharmacokinetic + pair-level checks

Timing optimizations

Berberine

With each meal (split 3×)

Short half-life (~4h). Needs to be present during post-meal glucose absorption. Most effective split across meals. (Onset: ~1.5h, half-life: ~4h)

Coenzyme Q10

With fat-containing meal

Fat-soluble. Ubiquinol form has 3× better bioavailability than ubiquinone; fat co-ingestion further improves absorption. (Onset: ~6h, half-life: ~33h)

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Supplements

2 items

BerberineModerate

Daily •

Buy ingredient →

10000mg

Dyslipidemia — LDL, triglycerides, total cholesterol

Moderate

Population: Adults with dyslipidemia

Study type: Systematic review and meta-analysis of RCTs

Dose context: — (range: 900–1500 mg) • Duration: 4–24 weeks

Berberine reduced LDL cholesterol by 0.46 mmol/L, triglycerides by 0.34 mmol/L, & total cholesterol by 0.48 mmol/L across 18 RCTs; HDL changes differed by sex (increase in women, slight decrease in men). No serious adverse events reported.

Citation: Blais JE, Huang X, Zhao JV. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs. 2023;83(5):403-427.•DOI: 10.1007/s40265-023-01841-4•https://pubmed.ncbi.nlm.nih.gov/36941490/

Glycemic control in type 2 diabetes

Moderate

Population: Adults with type 2 diabetes

Study type: Systematic review and meta-analysis of RCTs

Dose context: — (range: 500–1500 mg) • Duration: 8–24 weeks

Berberine reduced fasting plasma glucose by 0.82 mmol/L, HbA1c by 0.63%, & 2-hour postprandial glucose by 1.16 mmol/L across 37 RCTs (n=3048); glucose-lowering effect correlated with baseline glucose levels.

Citation: Xie W, Su F, Wang G, et al. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Front Pharmacol. 2022;13:1015045.•DOI: 10.3389/fphar.2022.1015045•https://pubmed.ncbi.nlm.nih.gov/36467075/

Coenzyme Q10Moderate

Daily •

Buy ingredient →

200mg

Morbidity & mortality in chronic heart failure

Moderate

Population: Adults with moderate-to-severe chronic heart failure

Study type: Randomized double-blind placebo-controlled trial (Q-SYMBIO)

Dose context: 300 mg typical • Duration: 2 years

CoQ10 100 mg three times daily over 2 years reduced major adverse cardiovascular events (15% vs 26% placebo) & all-cause mortality (10% vs 18% placebo; RR 0.58, 95% CI 0.35–0.95) in addition to standard therapy.

Citation: Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-9.•DOI: 10.1016/j.jchf.2014.06.008•https://pubmed.ncbi.nlm.nih.gov/25282031/

Landmark RCT; conducted in patients on background heart failure therapy.

Statin-associated muscle symptoms (myalgia, weakness, cramps)

Low

Population: Adults experiencing statin-induced myopathy

Study type: Systematic review and meta-analysis of RCTs

Dose context: —

CoQ10 supplementation significantly improved statin-associated muscle pain (WMD −1.60), weakness (WMD −2.28), cramps (WMD −1.78), & tiredness (WMD −1.75) across 12 RCTs (n=575), though plasma creatine kinase was not significantly reduced.

Citation: Qu H, Guo M, Chai H, et al. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018;7(19):e009835.•DOI: 10.1161/JAHA.118.009835•https://pubmed.ncbi.nlm.nih.gov/30371340/

Symptom improvement without biochemical marker change; overall evidence quality is low due to small trial sizes.